This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Pelvic bones, sacrum and coccyx
CD2_BENIGN_PELVIC_BONES_SACRUM_COCCYX_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D16
- Name in latin
- Neoplasma benignum ossis coxae, ossis sacri sive ossis coccygis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Pelvic bones, sacrum and coccyx
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Pelvic bones, sacrum and coccyx
- Benign neoplasm of bone and articular cartilage
- Benign neoplasm of bone and articular cartilage
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 140 | 90 | 50 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | 44.38 | 42.95 | 46.96 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 114
- Matched controls
- 1140
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D16.8
ICD-10 Finland
Benign neoplasm: Pelvic bones, sacrum and coccyx
+∞
106.6
85
*
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
71.2
20.8
23
*
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
42.8
19.8
24
7
21305
ICD-8 Finland
Benign neoplasm of bone and cartilage, Pelvis, sacri, coccygis
+∞
17.1
16
*
NER20
NOMESCO Finland
Incomplete excision of soft tissue tumour of pelvis
+∞
16.0
15
*
2136A
ICD-9 Finland
Benign neoplasm of bone and articular cartilage, Pelvic bones, sacrum and coccyx
+∞
14.9
14
*
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
145.3
12.7
13
*
NE1AA
NOMESCO Finland
Pelvis X-ray examination
10.4
12.6
25
30
NE1AD
NOMESCO Finland
Pelvis and hip bones CT examination
24.4
11.0
15
7
130
Kela drug reimbursment
Malignant tumour
+∞
10.6
10
*
NE1DG
NOMESCO Finland
Pelvic, hip and femur very extensive MRI examination with high intensity magnet
+∞
8.4
8
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
7.4
7
*
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
8.5
7.2
15
20
N02AA05
ATC
oxycodone; systemic
5.2
6.6
20
45
NEA20
NOMESCO Finland
Exploration of soft tissue of pelvis,v
73.8
6.5
7
*
9102
FHL
Trepanation or removal of the local bone process
19.3
6.4
9
5
D16.2
ICD-10 Finland
Benign neoplasm: Long bones of lower limb
28.4
6.3
8
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
6.3
6
*
9101
FHL
Bone biopsy
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
99
599
3.23
9.36
7.7
6.0
3.9
4.1
e9/l
0.25
93
520
79
475
2.52
6.69
6.0
4.8
1.2
1.2
mmol/l
0.18
67
408
72
416
2.50
6.63
6.0
4.3
1.2
1.2
mmol/l
0.24
67
378
17
45
4.16
6.02
1.2
1.6
—
—
—
0
0
78
517
2.15
4.69
5.8
3.3
9.4
11.0
umol/l
1.62
73
485
71
455
2.14
4.65
4.3
3.5
—
—
—
0
0
79
528
2.14
4.63
4.5
3.3
0.0
0.0
estimate
0.00
14
103
16
51
3.41
4.36
2.3
1.4
—
—
—
0
0
26
112
2.62
4.24
10.0
6.2
—
—
—
0
0
9
13
7.31
4.23
1.2
1.2
—
—
—
0
0
113
893
2.38
4.05
3.9
3.8
15.1
14.7
pmol/l
1.16
106
818
108
839
2.26
4.02
4.7
3.8
8.6
10.2
mm/h
1.17
102
783
20
77
2.86
4.01
2.3
2.2
54.3
67.6
ml/min/173m2
0.96
12
34
64
414
2.01
3.91
4.8
3.4
—
—
—
0
0
52
314
2.04
3.83
3.8
1.9
2.4
2.4
mmol/l
0.33
47
268
29
141
2.33
3.65
1.8
1.6
—
—
—
0
0
84
608
1.95
3.61
4.8
3.4
6.4
6.5
mmol/l
0.23
78
551
66
442
1.93
3.57
2.6
2.2
87.5
78.9
nmol/l
1.16
61
399
77
543
1.93
3.56
4.5
3.4
0.0
0.0
estimate
0.00
13
99
76
538
1.90
3.44
5.4
4.8
0.0
0.0
estimate
0.00
15
103
45
267
2.01
3.43
2.4
2.9
534.0
1284.4
ng/l
1.68
37
223
41
236
2.04
3.39
1.7
2.1
2.8
2.9
mg/l
0.15
33
194
52
326
1.95
3.38
2.3
2.1
56.3
58.5
u/l
0.22
47
294
37
207
2.07
3.29
2.4
1.8
—
—
—
0
0
9
20
4.73
3.17
1.6
1.5
54.9
67.3
pmol/l
—
9
20
9
20
4.73
3.17
1.6
1.2
—
—
—
0
0
125
1075
2.52
3.00
5.0
4.4
1.7
3.0
mu/l
0.58
117
996
58
392
1.82
2.91
3.5
3.4
17.8
44.9
ng/l
1.72
39
251
7
13
5.60
2.90
1.0
1.0
—
—
—
0
0
7
13
5.60
2.90
1.0
1.0
—
—
—
0
0
21
98
2.34
2.88
2.0
1.7
449.2
372.5
nmol/l
0.96
21
90
44
274
1.88
2.85
6.0
3.4
0.0
0.0
estimate
0.00
14
103
20
92
2.37
2.83
1.6
1.5
—
—
—
0
0
20
94
2.32
2.70
1.6
1.5
—
—
—
0
0
52
356
1.73
2.42
4.7
3.0
—
—
—
0
0
128
1141
2.42
2.33
18.2
11.4
139.9
139.8
mmol/l
0.21
123
1111
128
1145
2.38
2.23
18.3
11.4
4.0
4.0
mmol/l
0.60
123
1113
58
419
1.66
2.17
2.0
1.8
102.8
95.0
pmol/l
0.52
32
211
128
1161
2.20
1.88
16.1
9.7
18.9
20.1
mg/l
0.17
108
860
42
294
1.61
1.73
1.4
1.3
0.6
1.8
u/ml
1.04
15
84
7
28
2.58
1.47
1.7
1.4
—
—
—
0
0
63
500
1.47
1.43
3.0
2.6
125.8
89.6
ug/l
0.41
58
458
5
17
3.01
1.37
1.0
1.1
—
—
—
0
0
9
42
2.22
1.36
1.4
1.4
—
—
—
0
0
11
55
2.09
1.31
1.5
1.4
—
—
—
0
0
10
48
2.17
1.31
1.6
1.6
—
—
—
0
0
5
19
2.69
1.22
2.8
2.5
—
—
—
0
0
5
21
2.43
1.10
2.0
1.3
—
—
—
0
0
14
82
1.79
1.10
7.8
5.6
4.8
5.1
kpa
0.78
14
75
14
82
1.79
1.10
7.7
5.6
11.9
11.9
kpa
0.00
14
75
31
225
1.49
1.07
1.4
1.3
24.0
36.5
iu/ml
—
8
77
9
48
1.93
1.02
5.4
5.0
24.5
24.6
mmol/l
—
9
42
116
1067
1.51
1.02
14.5
9.1
84.7
84.1
ml/min/173m2
0.10
100
847
7
35
2.05
1.01
1.4
1.1
—
—
—
0
0
128
1205
1.73
1.00
19.8
11.3
73.8
74.9
umol/l
0.21
128
1205
34
255
1.44
1.00
1.7
1.6
3.7
0.8
mg/l
0.45
23
187
26
185
1.50
0.99
4.3
3.5
20.3
24.4
%
0.72
13
71
24
169
1.51
0.96
3.0
2.7
1.4
0.8
e6/l
0.20
16
87
8
42
1.96
0.90
2.0
1.9
—
—
—
0
0
8
42
1.96
0.90
2.0
1.8
—
—
—
0
0
93
833
1.35
0.88
3.1
3.5
—
—
—
0
0
0
26
0.00
0.79
0.0
1.5
—
—
—
0
0
5
23
2.22
0.77
1.0
2.3
—
—
—
0
0
5
26
1.96
0.71
1.4
1.1
13.0
2.8
e6/l
—
5
19
5
26
1.96
0.71
1.4
1.3
1.2
50.0
e6/l
—
5
19
27
208
1.37
0.69
1.5
1.4
—
—
—
0
0
115
1079
1.37
0.69
4.1
3.8
1.3
1.3
mmol/l
0.01
108
1007
36
291
1.32
0.68
3.4
2.9
2.2
0.4
e6/l
0.50
29
208
7
44
1.62
0.66
1.1
2.2
—
—
—
0
0
11
71
1.60
0.64
7.9
4.6
1.4
1.3
mmol/l
0.14
11
66
8
50
1.64
0.62
3.3
3.1
1.8
1.5
mmol/l
—
8
33
8
54
1.51
0.58
3.3
3.0
5.3
5.0
kpa
—
8
48
16
117
1.41
0.55
4.3
4.4
35.9
31.8
%
0.93
11
75
27
219
1.29
0.50
1.3
1.3
27.3
5.9
u/ml
0.65
17
85
118
1126
1.31
0.49
4.6
4.2
1.4
1.5
mmol/l
0.75
113
1060
7
48
1.48
0.47
1.3
1.6
—
—
—
0
0
18
139
1.34
0.46
2.8
2.3
0.5
0.8
ug/l
1.56
11
78
12
86
1.43
0.46
1.6
1.7
—
—
—
0
0
120
1152
1.29
0.44
5.1
4.6
2.6
2.8
mmol/l
2.40
115
1079
118
1133
1.26
0.41
4.7
4.2
4.4
4.7
mmol/l
3.96
113
1069
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
32
273
1.22
0.40
1.8
1.6
—
—
—
0
0
17
135
1.30
0.37
1.7
1.7
26.6
29.2
s
1.53
17
130
6
41
1.48
0.36
1.7
2.1
—
—
—
0
0
6
45
1.35
0.34
1.3
1.5
—
—
—
0
0
6
45
1.35
0.34
1.3
1.5
—
—
—
0
0
6
45
1.35
0.34
1.3
1.5
—
—
—
0
0
13
102
1.30
0.31
1.8
2.0
—
—
—
0
0
12
95
1.29
0.27
4.9
3.0
—
—
—
0
0
19
160
1.22
0.27
4.2
3.0
0.3
2.8
e6/l
2.12
12
79
11
138
0.78
0.27
2.3
1.8
—
—
—
0
0
9
72
1.27
0.26
1.0
1.0
—
—
—
0
0
5
37
1.36
0.24
1.8
1.2
2.6
3.0
g/l
—
5
31
5
39
1.29
0.23
1.8
1.2
—
—
—
0
0
5
39
1.29
0.23
1.8
1.2
4.0
3.9
g/l
—
5
31
5
39
1.29
0.23
1.8
1.2
6.6
7.7
g/l
—
5
32
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
6
51
1.18
0.19
1.3
1.4
—
—
—
0
0
108
1100
0.92
0.11
14.8
10.7
40.5
40.5
%
0.00
77
853
17
154
1.12
0.10
2.0
1.7
1.8
1.5
%
0.79
17
138
6
74
0.80
0.08
3.5
2.1
9.8
13.9
nmol/l
—
6
69
8
77
1.04
0.07
1.5
1.5
—
—
—
0
0
83
814
1.05
0.06
3.2
2.8
30.8
41.4
u/l
2.61
74
776
110
1112
0.95
0.05
4.9
4.1
6.0
5.9
mmol/l
0.21
99
1026
18
170
1.07
0.04
1.8
2.1
—
—
—
0
0
21
204
1.03
0.00
3.4
3.4
12.8
76.6
ng/l
1.22
12
146
105
1048
1.01
0.00
7.0
5.5
40.3
39.3
mmol/mol
0.51
98
990
18
185
0.97
0.00
1.9
2.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
49
1.02
0.00
2.0
2.4
34.0
42.6
u/l
—
5
42
0
7
0.00
0.00
0.0
1.1
—
9.8
—
0
7
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
121.6
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
8
84
0.95
0.00
1.1
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_PELVIC_BONES_SACRUM_COCCYX_EXALLC – Benign neoplasm: Pelvic bones, sacrum and coccyx
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).